The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
BJD, 2023.
Oras A. Alabas, Kayleigh J. Mason, Zenas Z.N. Yiu, Richard B. Warren, Nick Dand, Jonathan N.W.N. Barker, Catherine H. Smith, Christopher E.M. Grifï¬ths, the BADBIR and BSTOP study group.
Read publication: BJD
Related
Biosimilars for the Treatment of Psoriasis A Systematic Review of Clinical Trials and Observational ...
Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for pa...
Risk of Major Cardiovascular Events in Patients With Psoriasis Receiving Biologic Therapies: A Prosp...
0 Comments